MOUNJARO 15 mg/.5mL (Tirzepatide INJECTION, SOLUTION) 15 mg/.5mL

Tirzepatide, the active ingredient in MOUNJARO, is a dual GIP and GLP-1 receptor agonist. It selectively binds to and activates both the GIP and GLP-1 receptors, enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner. This action helps lower blood sugar levels and reduce body weight.

The usual dose of MOUNJARO 15 mg/0.5 mL is determined by the prescriber based on the patient's individual needs and response to treatment. The recommended starting dosage is 2.5 mg injected subcutaneously once weekly, with dose increases in 2.5 mg increments after at least 4 weeks on the current dose.

Based on animal studies, MOUNJARO 15 mg/0.5 mL may cause fetal harm. It is not recommended for use during pregnancy. The safety of MOUNJARO during breastfeeding has not been established. Patients should consult their healthcare provider for personalized advice.

To order MOUNJARO 15 mg/0.5 mL from GNH India, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams across international markets and will ask the buyer to confirm trade or institutional credentials. The team will then reply with pricing, availability, shipping, and the import paperwork.

MOUNJARO 15 mg/0.5 mL is a dual GIP and GLP-1 receptor agonist, which differentiates it from other diabetes medications that may target only one of these receptors or use different mechanisms to lower blood sugar levels. Its dual action provides a unique approach to glycemic control and weight reduction.

MOUNJARO 15 mg/0.5 mL should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F). If needed, each single-dose pen or single-dose vial can be stored unrefrigerated at temperatures not to exceed 30°C (86°F) for up to 21 days. Do not freeze MOUNJARO and do not use if frozen. Store in the original carton to protect from light.

MOUNJARO 15 mg/0.5 mL is administered subcutaneously once weekly at any time of day, with or without meals. It can be injected in the abdomen, thigh, or have another person inject in the back of the upper arm. Rotate injection sites with each dose.

The most serious risks to watch for with MOUNJARO 15 mg/0.5 mL include acute pancreatitis, severe hypoglycemia when used with insulin secretagogues or insulin, hypersensitivity reactions, acute kidney injury due to volume depletion, severe gastrointestinal adverse reactions, and diabetic retinopathy complications in patients with a history of diabetic retinopathy.

MOUNJARO 15 mg/0.5 mL should not be used by patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It is also not recommended for patients with severe gastroparesis or a history of severe gastrointestinal disease.